Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) Net Income towards Common Stockholders (2016 - 2025)

CorMedix's Net Income towards Common Stockholders history spans 14 years, with the latest figure at -$11.8 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 194.07% year-over-year to -$11.8 million; the TTM value through Dec 2025 reached $137.7 million, up 829.8%, while the annual FY2025 figure was $137.3 million, 876.74% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$11.8 million at CorMedix, down from $108.5 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $108.5 million in Q3 2025 and bottomed at -$14.5 million in Q1 2024.
  • The 5-year median for Net Income towards Common Stockholders is -$2.8 million (2024), against an average of $5.1 million.
  • The largest annual shift saw Net Income towards Common Stockholders tumbled 255.32% in 2023 before it surged 4001.2% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$9.7 million in 2021, then increased by 15.03% to -$8.2 million in 2022, then dropped by 18.11% to -$9.7 million in 2023, then skyrocketed by 229.04% to $12.5 million in 2024, then crashed by 194.07% to -$11.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Net Income towards Common Stockholders are -$11.8 million (Q4 2025), $108.5 million (Q3 2025), and $20.3 million (Q2 2025).